Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth

Gastroenterology and Hepatology

Volumn 5, Issue 6, 2009, Pages 435-442

  Pimentel, Mark ^a   Morales, Walter ^a   Lezcano, Sheila ^a   Dai, Sun Chuan ^a   Low, Kimberly ^a   Yang, Janet ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Erythromycin; Irritable bowel syndrome; Migrating motor complexes; Small intestinal bacterial overgrowth; Tegaserod

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLAVULANIC ACID; DOXYCYCLINE; EES 200; ERYTHROMYCIN ETHYLSUCCINATE; NEOMYCIN; NORFLOXACIN; RIFAXIMIN; TEGASEROD; UNCLASSIFIED DRUG; VIVONEX;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL OVERGROWTH; BEDTIME DOSAGE; BREATH ANALYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; ELEMENTAL DIET; ERADICATION THERAPY; FEMALE; HUMAN; IRRITABLE COLON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RECURRENT DISEASE; REMISSION; SMALL INTESTINE; TREATMENT OUTCOME;

EID: 68349121339     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Drossman DA, Sandler RS, McKee DC, Lovitz AJ. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology. 1982;83:529-534.
2. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology. 1980;79:283-288.
3. Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2006;8:305-311. (Pubitemid 44184043)
4. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802-808. (Pubitemid 46854194)
5. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-419. (Pubitemid 36232393)
6. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333. (Pubitemid 43381675)
7. Pimentel M, Park S, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-563. (Pubitemid 46780934)
8. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639-2643. (Pubitemid 35471599)
9. Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59:1158-1166. (Pubitemid 8131071)
10. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463-468. (Pubitemid 30140843)
11. Degen L, Petrig C, Studer D, Schroller S, Beglinger C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil. 2005;17:821-826. (Pubitemid 41746520)
12. Müller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655-1666.
13. Novick J, Miner P, Krause R, Glebas K, Bliesath H, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16:1877-1888.
14. Kamm MA, Müller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol. 2005;100:362-372. (Pubitemid 40314521)
15. Johanson JF, Wald A, Tougas G, Chey WD, Novick JS, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol. 2004;2:796-805. (Pubitemid 39200718)
16. DiStefano M, Vos R, Janssens J, Tack JF. Effect of tegaserod, a 5HT4 receptor partial agonist, on interdigestive and post-prandial gastrointestinal motility in healthy volunteers. Gastroenterology. 2003;124:A163.
17. Otterson MF, Sarna SK. Gastrointestinal motor effects of erythromycin. Am J Physiol. 1990;259(3 pt 1):G355-G363.
18. Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49:73-77. (Pubitemid 38183748)
19. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and re-treatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53:169-174. (Pubitemid 350265666)
20. Szurszewski JH. A migrating electric complex of canine small intestine. Am J Physiol. 1969;217:1757-1763.
21. Kuperman DA, Sninsky CA, Lynch DE. Myoelectric activity of the small intestine during morphine dependence and withdrawal in rats. Am J Physiol. 1987;252:G562-G567.
22. Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, Visser MR, Verhoef J, et al. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg. 1998;228:188-193. (Pubitemid 30191713)